Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma.

导出 OA

翻译打印收藏纠错

作者： Vanessa,Andrés-Guerrero ^[1] ; Lucía,Perucho-González ^[2] ; Julián,García-Feijoo ^[3] ; Laura,Morales-Fernández ^[1] ; Federico,Saenz-Francés ^[2] ; Rocío,Herrero-Vanrell ^[3] ; Luis Pablo,Júlvez ^[1] ; Vicente Polo,Llorens ^[2] ; José María,Martínez-de-la-Casa ^[3] ; Anastasios-Georgios,Konstas ^[1]

作者单位： Ocular Pathology National Net OFTARED of the Institute of Health Carlos III, Madrid, Spain. ^[1] Department of Ophthalmology, Hospital Clínico San Carlos, Complutense University of Madrid, Madrid, Spain. ^[2] Sanitary Research Institute of the San Carlos Clinical Hospital, Madrid, Spain. ^[3] Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid, Spain. ^[4] Department of Ophthalmology, Hospital Universitario Miguel Servet, Saragossa, Spain. ^[5] Aragon Health Sciences Institute, Saragossa, Spain. ^[6] 1st and 3rd University Departments of Ophthalmology, AHEPA Hospital, Aristotle University of Thessaloniki, 1 Kyriakidi Street, 546 36, Thessaloniki, Greece. konstas@med.auth.gr. ^[7]

关键词 Aflibercept Angiogenesis Bevacizumab Glaucoma filtration surgery Neovascular glaucoma Ranibizumab VEGF Wound modulation

主题词血管生成抑制剂(Angiogenesis Inhibitors);化学疗法, 辅助(Chemotherapy, Adjuvant);青光眼, 新生血管性(Glaucoma, Neovascular);人类(Humans);治疗结果(Treatment Outcome);血管内皮生长因子A(Vascular Endothelial Growth Factor A)

DOI 10.1007/s12325-016-0461-z

PMID 28000166

发布时间 2018-12-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交